|
1
|
Younes A: Beyond chemotherapy: New agents
for targeted treatment of lymphoma. Nat Rev Clin Oncol. 8:85–96.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Manzur S, Cohen S, Haimovich J and
Hollander N: Enhanced therapeutic effect of B cell-depleting
anti-CD20 antibodies upon combination with in-situ dendritic cell
vaccination in advanced lymphoma. Clin Exp Immunol. 170:291–299.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Friedberg JW: New strategies in diffuse
large B-cell lymphoma: Translating findings from gene expression
analyses into clinical practice. Clin Cancer Res. 17:6112–6117.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Timmerman JM, Byrd JC, Andorsky DJ, et al:
A phase I dose-finding trial of recombinant interleukin-21 and
rituximab in relapsed and refractory low grade B-cell
lymphoproliferative disorders. Clin Cancer Res. 18:5752–5760. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fowler N and Oki Y: Developing novel
strategies to target B-cell malignancies. Am Soc Clin Oncol Educ
Book. 366–372. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ramsay AD and Rodriguez-Justo M: Chronic
lymphocytic leukaemia-the role of the microenvironment pathogenesis
and therapy. Br J Haematol. 162:15–24. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gupta P, Goldenberg DM, Rossi EA and Chang
CH: Multiple signaling pathways induced by hexavalent,
monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22
humanized antibodies correlate with enhanced toxicity to B-cell
lymphomas and leukemias. Blood. 116:3258–3267. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roschewski M, Dunleavy K and Wilson WH:
Diffuse large B cell lymphoma: Molecular targeted therapy. Int J
Hematol. 96:552–561. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kenkre VP and Kahl BS: The future of
B-cell lymphoma therapy: The B-cell receptor and its downstream
pathways. Curr Hematol Malig Rep. 7:216–220. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sison EA, Rau RE, McIntyre E, Li L, Small
D and Brown P: MLL-rearranged acute lymphoblastic leukaemia stem
cell interactions with bone marrow stroma promote survival and
therapeutic resistance that can be overcome with CXCR4 antagonism.
Br J Haematol. 160:785–797. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen L, Monti S, Juszczynski P, et al: SYK
inhibition modulates distinct PI3K/AKT-dependent survival pathways
and cholesterol biosynthesis in diffuse large B cell lymphomas.
Cancer Cell. 23:826–838. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Irish JM, Myklebust JH, Alizadeh AA, et
al: B-cell signaling networks reveal a negative prognostic human
lymphoma cell subset that emerges during tumor progression. Proc
Natl Acad Sci USA. 107:12747–12754. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Young RM and Staudt LM: Targeting
pathological B cell receptor signalling in lymphoid malignancies.
Nat Rev Drug Discov. 12:229–243. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shain KH and Tao J: The B-cell receptor
orchestrates environment-mediated lymphoma survival and drug
resistance in B-cell malignancies. Oncogene. 33:4107–4113. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rickert RC: New insights into pre-BCR and
BCR signalling with relevance to B cell malignancies. Nat Rev
Immunol. 13:578–591. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choi MY and Kipps TJ: Inhibitors of B-cell
receptor signaling for patients with B-cell malignancies. Cancer J.
18:404–410. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stevenson FK, Krysov S, Davies AJ, et al:
B-cell receptor signaling in chronic lymphocytic leukemia. Blood.
118:4313–4320. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen L, Huynh L, Apgar J, et al: ZAP-70
enhances IgM signaling independent of its kinase activity in
chronic lymphocytic leukemia. Blood. 111:2685–2692. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Depoil D, Fleire S, Treanor BL, et al:
CD19 is essential for B cell activation by promoting B cell
receptor-antigen microcluster formation in response to
membrane-bound ligand. Nat Immunol. 9:63–72. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Niiro H and Clark EA: Regulation of B-cell
fate by antigen-receptor signals. Nat Rev Immunol. 2:945–956. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Humphries LA, Dangelmaier C, Sommer K, et
al: Tec kinases mediate sustained calcium influx via site-specific
tyrosine phosphorylation of the phospholipase Cgamma Src homology
2-Src homology 3 linker. J Biol Chem. 279:37651–37661. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hashimoto A, Okada H, Jiang A, et al:
Involvement of guanosine triphosphatases and phospholipase C-gamma2
in extracellular signal-regulated kinase, c-Jun NH2-terminal
kinase, and p38 mitogen-activated protein kinase activation by the
B cell antigen receptor. J Exp Med. 188:1287–1295. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shinohara M, Koga T, Okamoto K, et al:
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by
linking RANK and ITAM signals. Cell. 132:794–806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Davis RE, Ngo VN, Lenz G, et al: Chronic
active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Nature. 463:88–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khan WN: Regulation of B lymphocyte
development and activation by Bruton's tyrosine kinase. Immunol
Res. 23:147–156. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hamblin TJ, Davis Z, Gardiner A, Oscier DG
and Stevenson FK: Unmutated Ig V(H) genes are associated with a
more aggressive form of chronic lymphocytic leukemia. Blood.
94:1848–1854. 1999.PubMed/NCBI
|
|
27
|
Gobessi S, Laurenti L, Longo PG, et al:
ZAP-70 enhances B-cell-receptor signaling despite absent or
inefficient tyrosine kinase activation in chronic lymphocytic
leukemia and lymphoma B cells. Blood. 109:2032–2039. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Genevier HC, Hinshelwood S, Gaspar HB, et
al: Expression of Bruton's tyrosine kinase protein within the B
cell lineage. Eur J Immunol. 24:3100–3105. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vargas L, Hamasy A, Nore BF and Smith CI:
Inhibitors of BTK and ITK: State of the new drugs for cancer,
autoimmunity and inflammatory diseases. Scand J Immunol.
78:130–139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
O'Hayre M, Salanga CL, Kipps TJ, et al:
Elucidating the CXCL12/CXCR4 signaling network in chronic
lymphocytic leukemia through phosphoproteomics analysis. PLoS One.
5:e117162010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Redondo-Muñoz J, Escobar-Díaz E, Samaniego
R, et al: MMP-9 in B-cell chronic lymphocytic leukemia is
up-regulated by alpha4beta1 integrin or CXCR4 engagement via
distinct signaling pathways, localizes to podosomes, and is
involved in cell invasion and migration. Blood. 108:3143–3151.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Richards KL, Motsinger-Reif AA, Chen HW,
et al: Gene profiling of canine B-cell lymphoma reveals germinal
center and postgerminal center subtypes with different survival
times, modeling human DLBCL. Cancer Res. 73:5029–5039. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Herman SE, Sun X, McAuley EM, et al:
Modeling tumor-host interactions of chronic lymphocytic leukemia in
xenografted mice to study tumor biology and evaluate targeted
therapy. Leukemia. 27:2311–2321. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chang BY, Huang MM, Francesco M, et al:
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates
autoimmune arthritis by inhibition of multiple effector cells.
Arthritis Res Ther. 13:R1152011. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee KG, Xu S, Wong ET, Tergaonkar V and
Lam KP: Bruton's tyrosine kinase separately regulates NFkappaB
p65RelA activation and cytokine interleukin (IL)-10/IL-12
production in TLR9-stimulated B cells. J Biol Chem.
283:11189–11198. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mráz M, Doubek M and Mayer J: Inhibition
of B cell receptor signaling: A first targeted therapeutic approach
for chronic lymphocytic leukemia and other B cell lymphomas. Klin
Onkol. 26:179–185. 2013.(In Czech). View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tai YT, Chang BY, Kong SY, et al: Bruton
tyrosine kinase inhibition is a novel therapeutic strategy
targeting tumor in the bone marrow microenvironment in multiple
myeloma. Blood. 120:1877–1887. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Herman SE, Gordon AL, Hertlein E, et al:
Bruton tyrosine kinase represents a promising therapeutic target
for treatment of chronic lymphocytic leukemia and is effectively
targeted by PCI-32765. Blood. 117:6287–6296. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schwamb J, Feldhaus V, Baumann M, et al:
B-cell receptor triggers drug sensitivity of primary CLL cells by
controlling glucosylation of ceramides. Blood. 120:3978–3985. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang Y, Shaffer AL III, Emre NC, et al:
Exploiting synthetic lethality for the therapy of ABC diffuse large
B cell lymphoma. Cancer Cell. 21:723–737. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dasmahapatra G, Patel H, Dent P, et al:
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765
synergistically increases proteasome inhibitor activity in diffuse
large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells
sensitive or resistant to bortezomib. Br J Haematol. 161:43–56.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rushworth SA, Bowles KM, Barrera LN, et
al: BTK inhibitor ibrutinib is cytotoxic to myeloma and potently
enhances bortezomib and lenalidomide activities through NF-κB. Cell
Signal. 25:106–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
de Rooij MF, Kuil A, Geest CR, et al: The
clinically active BTK inhibitor PCI-32765 targets B-cell receptor-
and chemokine-controlled adhesion and migration in chronic
lymphocytic leukemia. Blood. 119:2590–2594. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sabine P, Balasubramanian S, Pham LV, et
al: Activity of Bruton's tyrosine kinase (Btk) inhibitor PCI-32765
in mantle cell lymphoma (MCL) identifies Btk as a novel therapeutic
target. Blood (ASH Annual Meeting Abstracts). 118:36882011.
|
|
45
|
Honigberg LA, Smith AM, Sirisawad M, et
al: The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell
activation and is efficacious in models of autoimmune disease and
B-cell malignancy. Proc Natl Acad Sci USA. 107:13075–13080. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
O'Brien SMD, Furman RR, Coutre SE, et al:
Ibrutinib as initial therapy for elderly patients with chronic
lymphocytic leukaemia or small lymphocytic lymphoma: An open-label,
multicentre, phase 1b/2 trial. Lancet Oncol. 15:48–58. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Advani RH, Buggy JJ, Sharman JP, et al:
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has
significant activity in patients with relapsed/refractory B-cell
malignancies. J Clin Oncol. 31:88–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Byrd JC, Furman RR, Coutre SE, et al:
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic
Leukemia. N Engl J Med. 369:32–42. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang L, Martin P, Blum KA, et al: The
Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as
single-agent therapy in previously-treated mantle cell lymphoma
(MCL): Preliminary results of a phase II trial. Blood (ASH Annual
Meeting Abstracts). 118:4422011.
|
|
50
|
Staudt LM, Dunleavy K, Buggy JJ, et al:
The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 modulates
chronic active BCR signaling and induces tumor regression in
relapsed/refractory ABC DLBCL. Blood (ASH Annual Meeting
Abstracts). 118:31742011.
|
|
51
|
Wilson WH, Gerecitano JF, Goy A, et al:
The Bruton's tyrosine kinase (BTK) inhibitor, Ibrutinib
(PCI-32765), Has Preferential activity in the ABC subtype of
relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL):
Interim results of a multicenter, open-label, phase 2 study. Blood
(ASH Annual Meeting Abstracts). 120:6862012.
|
|
52
|
Fowler NH, Advani RH, Sharman JP, et al:
The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is
active and tolerated in relapsed follicular lymphoma. Blood (ASH
Annual Meeting Abstracts). 120:1562012.
|
|
53
|
Jaglowski SM, Jones JA, Flynn JM, et al: A
phase Ib/II study evaluating activity and tolerability of BTK
inhibitor PCI-32765 and ofatumumab in patients with chronic
lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and
related diseases. J Clin Oncol (2012 ASCO Annual Meeting).
30:65082012.
|
|
54
|
O'Brien S, Burger JA, Blum KA, et al: The
Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable
responses in relapsed or refractory (R/R) chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL): Follow-up of a phase
Ib/II study. Blood (ASH Annual Meeting Abstracts). 120:9832011.
|
|
55
|
Burger JA, Keating MJ, Wierda WG, et al:
Safety and activity of ibrutinib plus rituximab for patients with
high-risk chronic lymphocytic leukaemia: A single-arm, phase 2
study. Lancet. 15:1090–1099. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
O'Brien SM, Barrientos JC, Flinn IW, et
al: Combination of the Bruton's tyrosine kinase (BTK) inhibitor
PCI-32765 with bendamustine(B)/rituximab (R) (BR) in patients (pts)
with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL):
Interim results of a phase Ib/IIstudy. J Clin Oncol (2012 ASCO
Annual Meeting). 30:65152012.
|
|
57
|
Brown JRBJ, Flinn I, et al: The Bruton's
tyrosine kinase (BTK) inhibitor ibrutinib combined with
bendamustine and rituximab is active and tolerable in patients with
relapsed/refractory CLL, interim results of a phase Ib/II study.
EHA Meeting Abstracts. 97:2012.
|
